NASH-TAG 2021
March 11-13, 2021
To help you get as much value from NASH-TAG 2021 as possible, we have identified several presentations and articles we find most interesting. Our daily podcasts will summarize these and discuss what they suggest for the future of NASH/NAFLD therapies.
Advanced Notification
S2-E59.4 – What Can We Do To Reshape a Potentially Disastrous Growth in Cirrhosis?
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”
S2-E59.3 – What’s next in Driving the Global Public Health Agenda for NAFLD?
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” This conversation focuses on the question “What’s Next,” which makes the scale of the challenge clear and compelling.
S2-E59.2 – Key Issues For the NAFLD Global Public Health Agenda: Prevalence and Cost Data
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”
S2-E59.1 – How the Global Health Agenda for NAFLD Was Developed
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” In this conversation, Jeff discusses how the study was executed, Jörn describes his role and Stephen Harrison comments from a physician’s perspective.
S2-E59 – Discuss the Global NAFLD Agenda publication With Lead Author Jeffrey Lazarus
The Surfers convene to discuss “Advancing the Public Health Agenda for NASH,” a paper recently published in Nature Reviews Gastroenterology and Hepatology, with lead author Jeffrey Lazarus and co-author Jörn Schattenberg.
S2-E58.3 – Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE
This episode focuses on the importance of NASH cirrhosis clinical trials. The conversation summarizes the status of four ongoing trials and addresses issues of disease naming and the value of incorporating MRE into trial designs.